BSX analysts cut targets across the board after Q3 miss

Boston Scientific absorbed a wall of analyst target-price cuts last week. The stock has since fallen to $43.50, sitting further below August's insider buying levels.

A coordinated sell-side reset

Ten firms lowered their price targets in two days after the October 28 earnings print. TD Cowen and Jefferies each cut their ratings from Buy to Hold, with Jefferies slashing its target from $60 to $46. TD Cowen moved from $56 to $46. Canaccord Genuity held its Buy but trimmed from $66 to $48. UBS stayed positive and cut from $67 to $57. The mean consensus price target now stands at $49.60, against a current share price of $43.50.

The stock fell 5.3% on earnings day. It has lost a further 3.5% over the past week. That compares to a median decline of roughly 0.5% among its closest peers. The stock is now trading near its lowest levels of the recent period, well below the $48.33 price at which CEO Michael Mahoney made his open-market purchase of 186,240 shares in August. That discretionary buy, documented in an earlier ORTEX note, remains the most visible insider conviction signal on the register.

Options hedging picks up

The put-call ratio jumped to 0.63 on November 3. The 20-day average sits at 0.44, and the z-score of 3.6 places this reading well outside the recent distribution. The PCR has not been this high since early October. Options buyers are paying up for downside protection at a rate that is statistically unusual for this stock.

Borrowing costs move, but borrow supply stays ample

The cost to borrow BSX shares has risen 54% over the past week to 0.52%. That is a sharp percentage move, but the absolute level remains low by any standard. Borrow availability is extremely loose, the lending pool holds far more shares than have been lent out, so the CTB move reflects incremental demand rather than any constraint on supply.

Short interest stands at 2.7% of free float, down roughly 7.5% over the past week. There is no short squeeze dynamic here. The SI level is unremarkable for a large-cap healthcare name.

Index rebalance footnote

ORTEX forecasts an 85% probability that BSX sees a share count increase in the CRSP US Mid index at the December 2026 Quarterly Review, implying around $613M of buying from index trackers around December 22. Separately, the agreed acquisition of Penumbra means ORTEX puts an 80% probability on a share count increase in S&P 500 index weights, with an estimated $378M of tracker buying around December 14 (dates estimated).

---

Data summary

• Price: $43.50, down 1.9% on the day, down 3.5% on the week
• Consensus mean target: $49.60 (down from prior levels across 10+ firms)
• Put-call ratio: 0.63, z-score 3.6 vs 20-day mean of 0.44
• Cost to borrow: 0.52%, up 54% over the week; availability remains extremely loose
• Short interest: 2.7% of free float, down 7.5% over the week
• Next earnings: February 3, 2027